<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773237</url>
  </required_header>
  <id_info>
    <org_study_id>17-001403</org_study_id>
    <nct_id>NCT03773237</nct_id>
  </id_info>
  <brief_title>Intralipid Versus SMOFlipid in HPN Patients</brief_title>
  <official_title>Randomized Prospective Trial Comparing Intralipid Versus SMOFlipid in New HPN Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will randomize all patients who are new to the Mayo Clinic HPN team to either
      standard lipid emulsion (Intralipid) or SMOFLipid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary aim is to assess the impact to direct bilirubin.

      Secondary aims will be to assess impact to other liver function studies, metabolic
      parameters, inflammatory marker, body weight, ability to meet caloric needs through TPN, and
      ability to obtain appropriate macronutrient composition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective Randomized Controlled</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The randomization list will be generated using http://www.randomization.com and blinded at enrollment using supplement codes. The study coordinator will hold the randomization codes and will be revealed to the investigators only after the statistical analysis is complete.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Direct Bilirubin Change is assessed</measure>
    <time_frame>At 12 weeks weeks</time_frame>
    <description>mg/dL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <condition>Intestinal Fistula</condition>
  <condition>Crohn Disease</condition>
  <condition>Intestinal Obstruction</condition>
  <arm_group>
    <arm_group_label>SMOFLipid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SMOFlipid is a lipid emulsion that contains a combination of soybean oil, medium chain triglycerides, olive oil, and fish oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IntraLipid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intralipid is a lipid emulsion that contains soybean oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SMOFLipid</intervention_name>
    <description>SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.</description>
    <arm_group_label>SMOFLipid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid</description>
    <arm_group_label>IntraLipid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly initiated Mayo Clinic HPN patient

          -  Able to provide informed consent

          -  Anticipated duration of HPN greater than 3 months,

          -  Infusion company is able to provide Smoflipid

        Exclusion Criteria:

          -  Age less than 18 years

          -  Pregnant and lactating women

          -  Failure to provide consent

          -  Patients with underlying liver dysfunction (defined as liver function studies equal to
             or more than 2 times upper limit of normal) or pathology as determined by primary
             investigator

          -  Patients with active malignancy

          -  Patients who are deemed to be on HPN for less than three months

          -  Patients who have previous proven addiction and dependence to alcohol/ heavy alcohol
             AND consumption/active use reported during last 12 months.

          -  Known hypersensitivity to fish, egg, soybean, or peanut protein, or to any of the
             active ingredients or excipients in Smoflipid

          -  Patients who will not be managed by the Mayo Clinic HPN team

          -  Patients who have active infection (as determined by the clinician) at the time of
             enrollment.

          -  Patients who have received Smoflipid greater than 4 weeks in the last 12 months prior
             to enrollment.

          -  Patients who have been on TPN greater than 4 weeks in the last 12 months prior to
             enrollment.

          -  Enrolled in another interventional study.

          -  Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides
             more than 1,000 mg/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manpreet S Mundi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manpreet S Mundi, MD</last_name>
    <phone>507-284-4080</phone>
    <email>Mundi.Manpreet@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vishakantha (Vishu) Murthy, PhD</last_name>
    <phone>507-255-8112</phone>
    <email>Murthy.Vishakantha@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manpreet Mundi, MD</last_name>
      <phone>507-284-4080</phone>
      <email>Mundi.Manpreet@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vishakantha Murthy, PhD</last_name>
      <phone>507-255-8112</phone>
      <email>Murthy.Vishakantha@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Manpreet S. Mundi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SMOF</keyword>
  <keyword>Intralipid</keyword>
  <keyword>Mixed oil emulsion</keyword>
  <keyword>Intestinal failure</keyword>
  <keyword>HPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Intestinal Obstruction</mesh_term>
    <mesh_term>Intestinal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

